Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.

By Nora D. Volkow, Linda Chang, Gene-Jack Wang, J. S. Fowler, M. Leonido-Yee, D. Franceschi, M. Sedler, S. Gatley, R. Hitzemann, Yu-Shin Ding and 3 more. American Journal of Psychiatry, 2001

945 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Epidemiology, Toxicology

View Paper: https://www.semanticscholar.org/paper/efb013f2f0b6fdc46d08098e3b1964bdf5730eca

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

In Epidemiology

In Toxicology

Nora D. Volkow

Citations in the corpus

A review of the clinical pharmacology of methamphetamine. (2009, background): “Abnormalities include inflammation [102], reduced neuronal density [103] and reduced density of dopaminergic markers such as DAT [67,104,105], D2 receptor [106], VMAT-2 [107] and the serotonergic marker SERT [108].”
Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits (2007, background): “Psychomotor slowing was the psychiatric symptom most strongly associated with reduced levels of DA transporter density in a PET study of methamphetamine abusers (Volkow et al. 2001).”
The mysterious motivational functions of mesolimbic dopamine. (2012, neutral): “, ‘‘avolition’’), stimulant withdrawal (Volkow et al., 2001), Parkinsonism (Friedman et al.”
Reward-related fMRI activation of dopaminergic midbrain is associated with enhanced hippocampus-dependent long-term memory formation (2005, background): “In humans, the reduced level of striatal dopamine in methamphetamine abusers is correlated with verbal memory impairment (Volkow et al., 2001).”
Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis (2007, background): “…above, a number of studies have shown relationships between duration of MA use and extent of dopaminergic dysfunction (Sekine et al. 2001, 2003; Volkow et al. 2001c), as well as at least partial recovery of dopamine terminal function, brain metabolism, and rCBF with extended abstinence (e.g.,…”
Major physical and psychological harms of methamphetamine use. (2008, background): “Cognitive deficits among methamphetamine-exposed individuals have been correlated with various indices of brain function in the cingulate, frontal and striatal regions [102,110,111], but the correlational nature of these findings prevents any causal inference that cognitive decrements are due to met”
METHAMPHETAMINE TOXICITY AND MESSENGERS OF DEATH (2009, background): “These abnormalities include persistent decreases in the levels of dopamine transporters (DAT) in the orbitofrontal cortex, dorsolateral prefrontal cortex, and the caudate-putamen (McCann et al., 1998, 2008; Sekine et al., 2003; Volkow et al., 2001a, 2001c).”
Structural Abnormalities in the Brains of Human Subjects Who Use Methamphetamine (2004, background): “…measures in control subjects, MA abusers exhibit lower levels of dopamine transporters in the striatum (McCann et al., 1998; Sekine et al., 2001; Volkow et al., 2001) and prefrontal cortex (Sekine et al., 2003) and differences in regional cerebral glucose metabolism (Volkow et al., 2001; London…”
Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. (2002, background): “We also reported lower striatal dopamine D2 receptor binding in heroin (59) and methamphetamine (60) abusers and in alcoholic subjects (61) (Figure 4).”